doi: 10.1161/hc3001.092040
(Circulation. 2001;104:455.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
Pioglitazone Enhances Cytokine-Induced Apoptosis in Vascular Smooth Muscle Cells and Reduces Intimal Hyperplasia
From the Department of Medicine, Asahikawa Medical College, Asahikawa, Japan.
Correspondence to Jun-ichi Kawabe, Department of Medicine, University of Medicine and Dentistry of New Jersey, 185 South Orange Ave, Newark, NJ 07103-2714. E-mail kawabeju{at}umdnj.edu
Background— Cytokines induce apoptosis in vascular disease lesions through enhancement of inducible nitric oxide (NO) synthase (iNOS) activation. The thiazolidinediones, novel insulin-sensitizing agents, have been demonstrated to modulate cytokine-induced NO production. We have investigated the role of pioglitazone in the apoptosis of vascular smooth muscle cells (VSMCs) in vitro and developed intimal hyperplasia in vivo.
Methods and Results— Pioglitazone (0.1 to 10 µmol/L) significantly enhanced cytokine-induced expression of iNOS and NO production in a dose-dependent manner in rat VSMCs, but 15-deoxy-
12,14-prostaglandin J2 (up to 10 µmol/L), a native peroxisome proliferator-activated receptor-
ligand, showed no effect. Pioglitazone also significantly enhanced reduction of cell viability, as evidenced by the increase in the number of TUNEL-positive cells. All of these effects of pioglitazone were blocked by treatment with N-monomethyl-L-arginine, an NO synthesis inhibitor. In an in vivo study with a balloon-injured rat carotid artery, neointimal thickness had reached maximum levels at 2 weeks after injury. Then, rats were fed with or without pioglitazone (3 mg · kg-1 · d-1) for an additional week. The ratio of intima to media area of carotid artery was significantly decreased by 30%, and the ratio of apoptotic cells in neointima was significantly increased in pioglitazone-treated rats compared with vehicle-treated control rats.
Conclusions— Pioglitazone enhanced apoptosis in an NO-dependent manner in cytokine-activated VSMCs and induced significant regression of intimal hyperplasia in balloon-injured rat carotid artery. It appears that pioglitazone is a potent apoptosis inducer in vascular lesions, providing a novel pharmacological strategy to prevent restenosis after vascular intervention.
Key Words: apoptosis • muscle, smooth • nitric oxide • vessels • restenosis
This article has been cited by other articles:
 |
|
 |
|
  E. Erdmann and R. Wilcox Pioglitazone and mechanisms of CV protection QJM, December 2, 2009; (2009) hcp168v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takagi, H. Okura, Y. Kobayashi, T. Kataoka, H. Taguchi, I. Toda, K. Tamita, A. Yamamuro, Y. Sakanoue, A. Ito, et al. A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study) J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 524 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Lee, T. Palaia, and L. Ragolia Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation Am J Physiol Cell Physiol, February 1, 2009; 296(2): C327 - C338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qiu, C. Depre, K. Ghosh, R. G. Resuello, F. F. Natividad, F. Rossi, A. Peppas, Y.-T. Shen, D. E. Vatner, and S. F. Vatner Mechanism of Gender-Specific Differences in Aortic Stiffness With Aging in Nonhuman Primates Circulation, August 7, 2007; 116(6): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ruiz, S. Redondo, A. Gordillo-Moscoso, and T. Tejerina Pioglitazone Induces Apoptosis in Human Vascular Smooth Muscle Cells from Diabetic Patients Involving the Transforming Growth Factor-beta/Activin Receptor-Like Kinase-4/5/7/Smad2 Signaling Pathway J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kosuge, G. Haraguchi, N. Koga, Y. Maejima, J.-i. Suzuki, and M. Isobe Pioglitazone Prevents Acute and Chronic Cardiac Allograft Rejection Circulation, June 6, 2006; 113(22): 2613 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wang, Z. Zhou, M. Zhang, L. Fan, F. Forudi, X. Zhou, W. Qu, A. M. Lincoff, A. M. Schmidt, E. J. Topol, et al. Peroxisome Proliferator-Activated Receptor {gamma} Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lim, C. J. Jin, M. Kim, S. S. Chung, H. S. Park, I. K. Lee, C. T. Lee, Y. M. Cho, H. K. Lee, and K. S. Park PPAR{gamma} Gene Transfer Sustains Apoptosis, Inhibits Vascular Smooth Muscle Cell Proliferation, and Reduces Neointima Formation After Balloon Injury in Rats Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 808 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Howarth, W. B. Wiehler, M. Pannirselvam, Y. Jiang, J. P. Berger, D. Severson, T. J. Anderson, and C. R. Triggle A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor {gamma} Agonist Reverses Endothelial Dysfunction in Diabetic (db/db-/-) Mice J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 364 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Barbato, B. S. Zuckerbraun, M. Overhaus, K. G. Raman, and E. Tzeng Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H228 - H236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Redondo, E. Ruiz, C. G. Santos-Gallego, E. Padilla, and T. Tejerina Pioglitazone Induces Vascular Smooth Muscle Cell Apoptosis Through a Peroxisome Proliferator-Activated Receptor-{gamma}, Transforming Growth Factor-{beta}1, and a Smad2-Dependent Mechanism Diabetes, March 1, 2005; 54(3): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Kawabe, S. Okumura, M.-C. Lee, J. Sadoshima, and Y. Ishikawa Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1845 - H1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Okada, N. Hasebe, Y. Aizawa, K. Izawa, J.-i. Kawabe, and K. Kikuchi Thermal Treatment Attenuates Neointimal Thickening With Enhanced Expression of Heat-Shock Protein 72 and Suppression of Oxidative Stress Circulation, April 13, 2004; 109(14): 1763 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lin, X. Zhu, F. L. Mclntee, H. Xiao, J. Zhang, M. Fu, and Y. E. Chen Interferon Regulatory Factor-1 Mediates PPAR{gamma}-Induced Apoptosis in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 257 - 263. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. V. Desouza, S. N. Murthy, J. Diez, B. Dunne, A. S. Matta, V. A. Fonseca, and D. B. McNamara Differential Effects of Peroxisome Proliferator Activator Receptor-{alpha} and {gamma} Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 297 - 305. [Abstract] [PDF]
|
|
|
|
|
|
K. Stephenson, J. Tunstead, A. Tsai, R. Gordon, S. Henderson, and H. M. Dansky Neointimal Formation After Endovascular Arterial Injury Is Markedly Attenuated in db/db Mice Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2027 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Phillips, K. G. Barringhaus, J. M. Sanders, Z. Yang, M. Chen, S. Hesselbacher, A. C. Czarnik, K. Ley, J. Nadler, and I. J. Sarembock Rosiglitazone Reduces the Accelerated Neointima Formation After Arterial Injury in a Mouse Injury Model of Type 2 Diabetes Circulation, October 21, 2003; 108(16): 1994 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bruemmer, F. Yin, J. Liu, J. P. Berger, T. Sakai, F. Blaschke, E. Fleck, A. J. Van Herle, B. M. Forman, and R. E. Law Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor {gamma} in Vascular Smooth Muscle Cells Circ. Res., August 22, 2003; 93 (4): e38 - e47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bruemmer, F. Yin, J. Liu, J. P. Berger, T. Kiyono, J. Chen, E. Fleck, A. J. Van Herle, B. M. Forman, and R. E. Law Peroxisome Proliferator-Activated Receptor {gamma} Inhibits Expression of Minichromosome Maintenance Proteins in Vascular Smooth Muscle Cells Mol. Endocrinol., June 1, 2003; 17(6): 1005 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakomura, H. Nagashima, Y. Aoka, K. Uto, A. Sakuta, S. Aomi, H. Kurosawa, T. Nishikawa, and H. Kasanuki Expression of Peroxisome Proliferator-Activated Receptor-{gamma} in Vascular Smooth Muscle Cells Is Upregulated in Cystic Medial Degeneration of Annuloaortic Ectasia in Marfan Syndrome Circulation, September 24, 2002; 106(12_suppl_1): I-259 - I-263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Marso Optimizing the diabetic formulary: beyond aspirin and insulin J. Am. Coll. Cardiol., August 21, 2002; 40(4): 652 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Need to Test the Arterial Inflammation Hypothesis Circulation, July 2, 2002; 106(1): 136 - 140. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kleschyov, M. Wendt, T. Munzel, D. A. Tulis, W. Durante, X. Liu, A. J. Evans, K. J. Peyton, and A. I. Schafer Heme Oxygenase-1-Mediated Protection: Potential Role of Nonheme Iron-Nitric Oxide Complexes * Response Circulation, June 25, 2002; 105 (25): e196 - e196. [Full Text] [PDF]
|
|